Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Tekmira Pharmaceuticals Corp (TKMR)  
$2.58 0.02 (0.77%) as of 4:30 Thu 3/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 85,817,000
Market Cap: 221.41(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.69 - $3.1
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 34,097 34,097 34,097 34,097
Total Sell Value $78,849 $78,849 $78,849 $78,849
Total People Sold 4 4 4 4
Total Sell Transactions 4 4 4 4
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 60
  Page 1 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Sofia Michael J. Chief Scientific Officer   •       –      –    2024-02-02 4 AS $2.31 $23,083 D/D (9,982) 1,485,121 5%     
   Hastings David C Chief Financial Officer   •       –      –    2024-02-02 4 AS $2.31 $22,184 D/D (9,593) 181,907 5%     
   Mcelhaugh Michael J. Interim President & CEO   •       •      –    2024-02-02 4 AS $2.31 $23,504 D/D (10,164) 1,504,793 5%     
   Sims Karen Chief Medical Officer   •       –      –    2024-02-02 4 AS $2.31 $10,078 D/D (4,358) 125,542 5%     
   Sofia Michael J. Chief Scientific Officer   •       –      –    2024-02-01 4 A $0.00 $0 D/D 109,500 1,495,103     -
   Naftzger J. Christopher General Counsel and CCO   •       –      –    2024-02-01 4 A $0.00 $0 D/D 95,100 95,100     -
   Hastings David C Chief Financial Officer   •       –      –    2024-02-01 4 A $0.00 $0 D/D 112,500 191,500     -
   Mcelhaugh Michael J. Interim President & CEO   •       •      –    2024-02-01 4 A $0.00 $0 D/D 123,800 1,514,957     -
   Sims Karen Chief Medical Officer   •       –      –    2024-02-01 4 A $0.00 $0 D/D 101,000 129,900     -
   Sims Karen Chief Medical OfficerOfficer   •       –      –    2023-07-10 3 IO $0.00 $0 D/D 0 28,900 -17%     
   Hastings David C Chief Financial Officer   •       –      –    2023-02-01 4 A $0.00 $0 D/D 79,000 79,000     -
   Collier William H. President and CEO   •       •      –    2023-02-01 4 A $0.00 $0 D/D 216,500 216,500     -
   Howard Elizabeth EVP, GC, Compliance   •       –      –    2023-02-01 4 A $0.00 $0 D/D 69,700 86,024     -
   Mcelhaugh Michael J. Chief Business Officer   •       –      –    2023-02-01 4 A $0.00 $0 D/D 83,700 1,391,157     -
   Sofia Michael J. Chief Scientific Officer   •       –      –    2023-02-01 4 A $0.00 $0 D/D 82,200 1,385,603     -
   Sofia Michael J. Chief Scientific Officer   •       –      –    2021-12-01 4 AS $5.09 $1,018,000 D/D (200,000) 1,303,403 -39%     
   Roivant Sciences Ltd. 10% Owner   –       –       •   2021-10-18 4 A $0.00 $0 D/D 22,833,922 38,847,462     -
   Mcelhaugh Michael J. Chief Business Officer   •       –      –    2021-02-09 4 AS $5.00 $100,000 D/D (20,000) 1,307,457 -30%     
   Mcelhaugh Michael J. Chief Business Officer   •       –      –    2020-12-14 4 AS $5.00 $200,032 D/D (40,000) 1,327,457 -33%     
   Mcelhaugh Michael J. Chief Business Officer   •       –      –    2020-07-23 4 AS $5.01 $100,200 D/D (20,000) 1,367,457 -36%     
   Murray Mark J. Director   –       •      –    2018-11-28 4 OE $1.35 $33,750 D/D 25,000 341,396     -
   Sofia Michael J. Chief Scientific Officer   •       –      –    2018-08-13 4/A S $9.51 $40,436 I/I (4,250) 167,162     -
   Sofia Michael J. Chief Scientific Officer   •       –      –    2018-08-13 4 S $9.51 $40,436 D/D (4,250) 1,499,153     -
   Sofia Michael J. Chief Scientific Officer   •       –      –    2018-07-11 4 AS $10.00 $100,000 D/D (10,000) 1,503,403     -
   Sofia Michael J. Chief Scientific Officer   •       –      –    2018-07-09 4 AS $8.91 $89,060 D/D (10,000) 1,513,403     -

  60 Records found
  1  2  3   
  Page 1 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed